Icotinib is the second line first generation EGFR TKI that was approved by China Food and Drug Administration (CFDA) in 2011, and because of its compatible efficacy and side effects as gefitinib [34], as well as its lower price, it is widely used in treating NSCLC in China. This evidence concerns the gene EGFR and non-small cell lung carcinoma.